| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 02/05/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:NOVN | Novan Inc |
| 01/05/2024 | 17:49 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:NOVN | Novan Inc |
| 25/03/2024 | 13:54 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NOVN | Novan Inc |
| 05/01/2024 | 15:23 | GlobeNewswire Inc. | Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis | NASDAQ:NOVN | Novan Inc |
| 11/12/2023 | 01:30 | GlobeNewswire Inc. | Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) | NASDAQ:NOVN | Novan Inc |
| 08/12/2023 | 15:15 | GlobeNewswire Inc. | Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions | NASDAQ:NOVN | Novan Inc |
| 06/12/2023 | 01:16 | GlobeNewswire Inc. | Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH | NASDAQ:NOVN | Novan Inc |
| 20/11/2023 | 07:15 | GlobeNewswire Inc. | Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH | NASDAQ:NOVN | Novan Inc |
| 17/07/2023 | 14:45 | GlobeNewswire Inc. | Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection | NASDAQ:NOVN | Novan Inc |
| 28/06/2023 | 00:30 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:NOVN | Novan Inc |
| 16/06/2023 | 23:02 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:NOVN | Novan Inc |
| 05/06/2023 | 15:00 | GlobeNewswire Inc. | Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders | NASDAQ:NOVN | Novan Inc |
| 31/05/2023 | 22:05 | GlobeNewswire Inc. | Novan Focuses Strategic Direction and Announces Restructuring | NASDAQ:NOVN | Novan Inc |
| 15/05/2023 | 12:56 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:NOVN | Novan Inc |
| 15/05/2023 | 12:45 | GlobeNewswire Inc. | Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:NOVN | Novan Inc |
| 08/05/2023 | 15:05 | GlobeNewswire Inc. | Novan to Report First Quarter 2023 Financial Results on May 15, 2023 | NASDAQ:NOVN | Novan Inc |
| 27/04/2023 | 15:10 | GlobeNewswire Inc. | Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹ | NASDAQ:NOVN | Novan Inc |
| 27/04/2023 | 15:00 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:NOVN | Novan Inc |
| 20/04/2023 | 15:00 | GlobeNewswire Inc. | Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD | NASDAQ:NOVN | Novan Inc |
| 30/03/2023 | 12:30 | GlobeNewswire Inc. | Novan Reports Full Year 2022 Financial Results and Provides Corporate Update | NASDAQ:NOVN | Novan Inc |
| 23/03/2023 | 14:00 | GlobeNewswire Inc. | Novan to Report Full Year 2022 Financial Results on March 30, 2023 | NASDAQ:NOVN | Novan Inc |
| 20/03/2023 | 14:38 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:NOVN | Novan Inc |
| 20/03/2023 | 00:00 | GlobeNewswire Inc. | Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset | NASDAQ:NOVN | Novan Inc |
| 16/03/2023 | 23:47 | GlobeNewswire Inc. | Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer | NASDAQ:NOVN | Novan Inc |
| 16/03/2023 | 21:15 | GlobeNewswire Inc. | Novan Announces Closing of $6.0 Million Registered Direct Offering | NASDAQ:NOVN | Novan Inc |
| 14/03/2023 | 13:30 | GlobeNewswire Inc. | Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference | NASDAQ:NOVN | Novan Inc |
| 14/03/2023 | 13:00 | GlobeNewswire Inc. | Novan Announces $6.0 Million Registered Direct Offering | NASDAQ:NOVN | Novan Inc |
| 08/03/2023 | 15:00 | GlobeNewswire Inc. | Novan Moves Forward with Unified Corporate Branding | NASDAQ:NOVN | Novan Inc |
| 07/03/2023 | 14:00 | GlobeNewswire Inc. | FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024 | NASDAQ:NOVN | Novan Inc |
| 18/01/2023 | 14:05 | GlobeNewswire Inc. | Novan to Present at the Virtual Investor 2023 Companies to Watch Event | NASDAQ:NOVN | Novan Inc |